Drug Type Monoclonal antibody |
Synonyms CSJ 148, CSJ148, LJP-53 + [5] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cytomegalovirus Infections | Phase 2 | US | 02 Jun 2015 | |
Cytomegalovirus Infections | Phase 2 | BE | 02 Jun 2015 | |
Cytomegalovirus Infections | Phase 2 | DE | 02 Jun 2015 | |
Cytomegalovirus Infections | Phase 2 | SG | 02 Jun 2015 | |
Cytomegalovirus Infections | Phase 2 | KR | 02 Jun 2015 | |
Cytomegalovirus Infections | Phase 2 | TW | 02 Jun 2015 |
NCT02268526 (Pubmed) Manual | Phase 2 | - | mxxazthwdu(lbdrlerjep): RR = 0.89 (90% CI, 0.61 - 1.31) | Negative | 24 Mar 2020 | ||
placebo | |||||||
Phase 2 | 86 | (Cohort 2: CSJ148) | uvrpknxbbw(gvehwbpnzh) = apelxrbtdn ehosirlvir (bbrhwdxlor, dskeqqmbxw - kgcgphzslc) View more | - | 26 Feb 2018 | ||
Placebo (Cohort 2: Placebo) | uvrpknxbbw(gvehwbpnzh) = igsollkdxa ehosirlvir (bbrhwdxlor, yuazotzwwm - gaaccjvmoy) View more |